LENZ THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.91 USD | +1.14% |
|
-1.67% | 0.00% |
| Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 406.3 | - | - |
| Enterprise Value (EV) 1 | 406.3 | 406.3 | 406.3 |
| P/E ratio | -7.39 x | -5.7 x | -8.35 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | 31.8 x | 7.84 x |
| EV / Revenue | - | 31.8 x | 7.84 x |
| EV / EBITDA | -8.61 x | -4.5 x | -5.53 x |
| EV / FCF | -9.67 x | -6.45 x | -13.1 x |
| FCF Yield | -10.3% | -15.5% | -7.63% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 25,534 | - | - |
| Reference price 2 | 15.91 | 15.91 | 15.91 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | 12.77 | 51.84 |
| EBITDA 1 | - | -47.19 | -90.2 | -73.5 |
| EBIT 1 | - | -50.74 | -63.33 | -57.07 |
| Operating Margin | - | - | -496.02% | -110.09% |
| Earnings before Tax (EBT) 1 | - | -46.08 | -76.89 | -53.46 |
| Net income 1 | -69.97 | -46.01 | -79.36 | -53.81 |
| Net margin | - | - | -621.57% | -103.79% |
| EPS 2 | -7.220 | -2.153 | -2.793 | -1.906 |
| Free Cash Flow 1 | - | -42 | -63 | -31 |
| FCF margin | - | - | -493.44% | -59.8% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA 1 | -16.08 | -12.93 | -9.975 | -8.205 | - | - |
| EBIT 1 | -16.09 | -12.81 | -11.77 | -10.07 | -15 | -19 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -16.65 | -10.98 | -10.04 | -9.456 | -13.81 | -17.9 |
| Net income 1 | -16.65 | -10.83 | -9.93 | -10.62 | -13.81 | -17.9 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -3.530 | -0.4246 | -0.3715 | -0.3433 | -0.5350 | -0.7550 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -42 | -63 | -31 |
| ROE (net income / shareholders' equity) | - | -1% | -11% | -0.51% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 0.02 | 0.02 | - |
| Capex / Sales | - | - | 0.13% | - |
| Announcement Date | 3/22/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
15.91
USD
Average target price
36.75
USD
Spread / Average Target
+130.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 406M | |
| +5.66% | 111B | |
| +11.23% | 105B | |
| -2.53% | 21.93B | |
| -12.15% | 22.34B | |
| -5.52% | 18.59B | |
| -36.52% | 18.12B | |
| -10.09% | 16.96B | |
| +3.33% | 13.7B | |
| +36.58% | 12.45B |
- Stock Market
- Equities
- LENZ Stock
- Financials LENZ Therapeutics, Inc.
